These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 37887257)
1. Antarctic Marine Bacteria as a Source of Anti-Biofilm Molecules to Combat ESKAPE Pathogens. Artini M; Papa R; Vrenna G; Trecca M; Paris I; D'Angelo C; Tutino ML; Parrilli E; Selan L Antibiotics (Basel); 2023 Oct; 12(10):. PubMed ID: 37887257 [TBL] [Abstract][Full Text] [Related]
3. Characterisation of ESKAPE Pathogens with Special Reference to Multidrug Resistance and Biofilm Production in a Nepalese Hospital. Pandey R; Mishra SK; Shrestha A Infect Drug Resist; 2021; 14():2201-2212. PubMed ID: 34163185 [TBL] [Abstract][Full Text] [Related]
4. Farnesol Emulsion as an Effective Broad-Spectrum Agent against ESKAPE Biofilms. Tan L; Ma R; Katz AJ; Levi N Antibiotics (Basel); 2024 Aug; 13(8):. PubMed ID: 39200078 [TBL] [Abstract][Full Text] [Related]
5. Clonal dispersion of Acinetobacter baumannii in an intensive care unit designed to patients COVID-19. Durán-Manuel EM; Cruz-Cruz C; Ibáñez-Cervantes G; Bravata-Alcantará JC; Sosa-Hernández O; Delgado-Balbuena L; León-García G; Cortés-Ortíz IA; Cureño-Díaz MA; Castro-Escarpulli G; Vélez-Reséndiz JM; Bello-López JM J Infect Dev Ctries; 2021 Jan; 15(1):58-68. PubMed ID: 33571146 [TBL] [Abstract][Full Text] [Related]
6. Differential anti-microbial secondary metabolites in different ESKAPE pathogens explain their adaptation in the hospital setup. Tiwari V; Meena K; Tiwari M Infect Genet Evol; 2018 Dec; 66():57-65. PubMed ID: 30227225 [TBL] [Abstract][Full Text] [Related]
7. Norfloxacin salts of carboxylic acids curtail planktonic and biofilm mode of growth in ESKAPE pathogens. Lowrence RC; Ramakrishnan A; Sundaramoorthy NS; Shyam A; Mohan V; Subbarao HMV; Ulaganathan V; Raman T; Solomon A; Nagarajan S J Appl Microbiol; 2018 Feb; 124(2):408-422. PubMed ID: 29178633 [TBL] [Abstract][Full Text] [Related]
8. Navigating ESKAPE Pathogens: Considerations and Caveats for Animal Infection Models Development. Yu H; Xu Y; Imani S; Zhao Z; Ullah S; Wang Q ACS Infect Dis; 2024 Jul; 10(7):2336-2355. PubMed ID: 38866389 [TBL] [Abstract][Full Text] [Related]
9. Antimicrobial Peptides Derived From Insects Offer a Novel Therapeutic Option to Combat Biofilm: A Review. Sahoo A; Swain SS; Behera A; Sahoo G; Mahapatra PK; Panda SK Front Microbiol; 2021; 12():661195. PubMed ID: 34248873 [TBL] [Abstract][Full Text] [Related]
10. Non-Antimicrobial Drugs: Etodolac as a Possible Antimicrobial or Adjuvant Agent Against ESKAPE Pathogens. Pereira SG; Domingues VS; Theriága J; Chasqueira MJ; Paixão P Open Microbiol J; 2018; 12():288-296. PubMed ID: 30288184 [TBL] [Abstract][Full Text] [Related]
12. Biofilm contamination of high-touched surfaces in intensive care units: epidemiology and potential impacts. Costa DM; Johani K; Melo DS; Lopes LKO; Lopes Lima LKO; Tipple AFV; Hu H; Vickery K Lett Appl Microbiol; 2019 Apr; 68(4):269-276. PubMed ID: 30758060 [TBL] [Abstract][Full Text] [Related]
13. Application of CRISPR-Cas system in the diagnosis and therapy of ESKAPE infections. Qian Y; Zhou D; Li M; Zhao Y; Liu H; Yang L; Ying Z; Huang G Front Cell Infect Microbiol; 2023; 13():1223696. PubMed ID: 37662004 [TBL] [Abstract][Full Text] [Related]
14. Metal Nanoparticle-Based Biosensors for the Early Diagnosis of Infectious Diseases Caused by ESKAPE Pathogens in the Fight against the Antimicrobial-Resistance Crisis. Gutiérrez-Santana JC; Rosas-Espinosa V; Martinez E; Casiano-García E; Coria-Jiménez VR Biosensors (Basel); 2024 Jul; 14(7):. PubMed ID: 39056615 [TBL] [Abstract][Full Text] [Related]
15. Bactericidal efficacy of atmospheric pressure non-thermal plasma (APNTP) against the ESKAPE pathogens. Flynn PB; Higginbotham S; Alshraiedeh NH; Gorman SP; Graham WG; Gilmore BF Int J Antimicrob Agents; 2015 Jul; 46(1):101-7. PubMed ID: 25963338 [TBL] [Abstract][Full Text] [Related]
16. Multidrug-Resistant and Virulent Organisms Trauma Infections: Trauma Infectious Disease Outcomes Study Initiative. Mende K; Akers KS; Tyner SD; Bennett JW; Simons MP; Blyth DM; Li P; Stewart L; Tribble DR Mil Med; 2022 May; 187(Suppl 2):42-51. PubMed ID: 35512375 [TBL] [Abstract][Full Text] [Related]
17. Antibacterial activity of medicinal plants against ESKAPE: An update. Bhatia P; Sharma A; George AJ; Anvitha D; Kumar P; Dwivedi VP; Chandra NS Heliyon; 2021 Feb; 7(2):e06310. PubMed ID: 33718642 [TBL] [Abstract][Full Text] [Related]
18. Alternatives for the treatment of infections caused by ESKAPE pathogens. da Rosa TF; Coelho SS; Foletto VS; Bottega A; Serafin MB; Machado CS; Franco LN; de Paula BR; Hörner R J Clin Pharm Ther; 2020 Aug; 45(4):863-873. PubMed ID: 32339305 [TBL] [Abstract][Full Text] [Related]
19. Antimicrobial Activity of Two Different Types of Silver Nanoparticles against Wide Range of Pathogenic Bacteria. Holubnycha V; Husak Y; Korniienko V; Bolshanina S; Tveresovska O; Myronov P; Holubnycha M; Butsyk A; Borén T; Banasiuk R; Ramanavicius A; Pogorielov M Nanomaterials (Basel); 2024 Jan; 14(2):. PubMed ID: 38251102 [TBL] [Abstract][Full Text] [Related]